Tan H.M.,Sime Darby Medical Center |
Tan H.M.,University of Malaya |
Tong S.F.,National University of Malaysia |
Ho C.C.,National University of Malaysia
Journal of Sexual Medicine | Year: 2012
Introduction. Sexual dysfunction in men, such as erectile dysfunction, hypogonadism, and premature ejaculation, generates considerable attention. Its association with physical and psychological health is an issue which should be addressed seriously. Aim. A review of the literature pertaining to the correlation between sexual dysfunction and physical and psychological health. Methods. PubMed search for relevant publications on the association between sexual dysfunction in men and physical and psychological health. Main Outcome Measure. Clinical and epidemiological evidence that demonstrates the association between sexual dysfunction in men and physical and psychological health. Results. Sexual dysfunction, i.e., erectile dysfunction, hypogonadism, and premature ejaculation, has been shown to be associated with physical and psychological health. There is a strong correlation between sexual dysfunction and cardiovascular disease, metabolic syndrome, quality of life, and depression. Conclusion. The association between men's sexual dysfunction and physical and psychological health is real and proven. Therefore, it should not be taken lightly but instead treated as a life-threatening medical problem. © 2011 International Society for Sexual Medicine.
Mohd-Yusuf Y.,University of Malaya |
Phipps M.E.,University of Selangor |
Chow S.K.,Sunway Medical Center |
Yeap S.S.,Sime Darby Medical Center
Immunology Letters | Year: 2011
We investigated the association of the HLA genes in Malaysian patients with systemic lupus erythematosus (SLE) and their associations with the clinical manifestations in 160 SLE patients (99 Chinese and 61 Malays) and 107 healthy control individuals (58 Chinese and 49 Malays) were studied. Sequence specific primer amplification (PCR-SSP) phototyping techniques were used to analyse 25 HLA-A allele groups, 31 HLA-DR allele groups and 9 HLA-DQ allele groups. Appreciable increases in allele frequencies of HLA-A*11, DRB1*0701, DRB1*1601-1606, DRB5*01-02 and DQB1*05, and decrease in HLA-DRB1*1101-1121, 1411, DRB1*1201-3, DRB1*1301-22, DRB3*0101, 0201, 0202, 0203, 0301 and DQB1*0301, 1304 in SLE patients compared with healthy control individuals. However, after Bonferroni correction (pc<0.05) only HLA-A*1101, 1102, DRB5*01-02, DQB1*05, DRB1*1201-3, DRB3*0101, 0201, 0202, 0203, 0301 and DQB1*0301, 0304 remained significant. Allele frequencies of DRB1*0701 and DRB4*0101101, 0102, 0103, DQB1*05, DRB1*1301-22, DRB3*0101, 0201, 0202, 0203, 0301 and DQB1*0301, 0304 were significantly increased in Malay SLE patients compared with healthy control individuals. In contrast, Chinese SLE patients had increased allele frequencies of DRB1*1601-1606, DQB1*05, DRB1*1201-3, DRB3*0101, 0201, 0202, 0203, 0301, DRB3*0101, 0201, 0202, 0203, 0301 and DQB1*0301, 0304 compared with healthy control individuals. HLA-A*6801-02 and DRB1*1601-1606 frequencies appeared elevated in a subset of patients with serositis and DRB1* 0401-1122 frequency was elevated in those displaying neurologic disorder. However, unequivocal evidence of these associations would require investigation of substantially larger cohorts. On the whole, our findings suggest that HLA allele associations with SLE are race specific in Malays and Chinese. © 2011 Elsevier B.V.
Selladurai B.M.,Sime Darby Medical Center
Neurology Asia | Year: 2011
Posttraumatic epilepsy accounts for about 20% of symptomatic epilepsy in the general population and about 5% patients referred to epilepsy centers. Mechanisms that can provoke posttraumatic seizures are still not well understood. The extent of focal tissue destruction is one of the key determinants of risk of seizures. Early posttraumatic seizures can worsen ischemic injury and increase intracranial pressure. Adverse sequelae of late posttraumatic seizures include a higher mortality and personality disorders. Whilst anticonvulsant prophylaxis of early seizures is recommended, such therapy is yet to be proven to prevent late posttraumatic seizures.
Choo G.-H.,Sime Darby Medical Center
EuroIntervention | Year: 2011
The drug-eluting balloon (DEB) is an exciting new technology that holds much promise. As an evolving technology undergoing intensive research, the device is being constantly refined and its numerous potential applications studied. Though initially created to fulfil specific needs in the coronary vasculature, there is great potential for its use in other vascular territories and structures including the management of valvular, congenital heart and neuro-interventional pathologies. In addition, the application of this device in conjunction with other existing technologies may enhance the clinical results. © Europa Edition 2011. All rights reserved.
Ho C.C.K.,National University of Malaysia |
Tong S.F.,National University of Malaysia |
Low W.Y.,University of Malaya |
Ng C.J.,University of Malaya |
And 5 more authors.
BJU International | Year: 2012
OBJECTIVE: • To evaluate the effect of i.m. injection of testosterone undecanoate 1000 mg over 12 months on the Aging Male Symptom (AMS) scale scores in men with testosterone deficiency syndrome (TDS). PATIENTS AND METHODS: • A total of 120 men > 40 years old with TDS (total testosterone < 12 nmol/L and total AMS scores ≥ 27) were randomized into i.m. injection of either placebo or testosterone undecanoate 1000 mg. • In all, 56 and 58 participants from the active treatment and placebo groups, respectively completed the study. • An i.m. injection of either placebo or testosterone undecanoate 1000 mg was given at weeks 0, 6, 18, 30 and 48. • Self-administered AMS questionnaires were completed at weeks 0, week 18 and week 48. RESULTS: • Improvement in the total AMS score was significantly greater in the treatment group than in the placebo group (F: 4.576, P = 0.017) over the 48-week period. • The mean (SD) total AMS score was 38.46 (11.85) at baseline and 33.59 (1.69) at 48 weeks for the placebo group, and 41.73 (12.73) at baseline and 32.61 (9.67) at 48 weeks for the treatment group. • The mean change in the total AMS score was -12.6% in the placebo group and -21.9% in the treatment group. • The mean psychological and somatovegetative domain scores decreased significantly more in the treatment group than in the placebo group (-2.8 vs -1.2, P = 0.03; and -3.2 vs -1.8, P = 0.016). • The difference in change between the randomized groups for the sexual domain scores followed the same trend, though the difference was not significant. CONCLUSION: • Long-acting testosterone is effective in improving health-related quality of life as assessed by the AMS scale in men with TDS. © 2011 The Authors BJU International © 2011 BJU International.